- Report
- March 2024
- 181 Pages
Global
From €3257EUR$3,374USD£2,794GBP
€3619EUR$3,749USD£3,104GBP
- Report
- August 2022
- 120 Pages
Global
From €4585EUR$4,750USD£3,933GBP
- Report
- March 2021
- 48 Pages
Global
€21234EUR$22,000USD£18,215GBP
- Report
- January 2019
- 212 Pages
Global
From €21234EUR$22,000USD£18,215GBP
- Report
- March 2018
- 17 Pages
Global
From €9652EUR$10,000USD£8,279GBP
- Report
- March 2019
- 195 Pages
Global
From €10612EUR$10,995USD£9,103GBP
- Report
- May 2020
- 173 Pages
Global
From €3475EUR$3,600USD£2,981GBP
- Report
- September 2019
- 70 Pages
Global
From €3137EUR$3,250USD£2,691GBP
The Evenity market is a subset of the Musculoskeletal Disorders Drugs market, which focuses on treatments for conditions such as osteoporosis, rheumatoid arthritis, and ankylosing spondylitis. Evenity is a biologic drug used to treat osteoporosis in postmenopausal women, and is designed to reduce the risk of fractures. It is administered as an intravenous infusion, and is typically used in combination with other treatments.
The Evenity market is highly competitive, with a number of companies offering similar treatments. These include Amgen, Eli Lilly, Merck, Novartis, and Pfizer. Each company has its own unique approach to the treatment of musculoskeletal disorders, and offers a range of products and services to meet the needs of patients. Show Less Read more